Avadel Pharmaceuticals
AVDL
About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Employees: 188
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
43% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 49
18% more capital invested
Capital invested by funds: $611M [Q1] → $719M (+$108M) [Q2]
3.62% more ownership
Funds ownership: 80.33% [Q1] → 83.95% (+3.62%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]
4% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 27
1% less funds holding
Funds holding: 172 [Q1] → 170 (-2) [Q2]
38% less call options, than puts
Call options by funds: $2.43M | Put options by funds: $3.91M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
HC Wainwright & Co.
Raghuram Selvaraju
|
$36
|
Buy
Maintained
|
5 Sep 2025 |
|
Wells Fargo
Benjamin Burnett
|
$16
|
Equal-Weight
Initiated
|
3 Sep 2025 |
|
UBS
Ashwani Verma
|
$20
|
Buy
Maintained
|
21 Aug 2025 |
Financial journalist opinion
Based on 7 articles about AVDL published over the past 30 days
